The Chicago Entrepreneur

FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic

The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.

Previous post Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Next post Cannabis stocks rally after AP reports DEA will propose reclassifying drug as Schedule III